Healio

VIDEO: Treatment outlook ‘rapidly changing’ in primary sclerosing cholangitis

Healio spoke with Marlyn Mayo, MD, about increased research focused on symptoms of primary sclerosing cholangitis presented at The Liver Meeting, as well as treatments being ...
Healio

VIDEO: Iqirvo may stabilize primary biliary cholangitis progression after long-term use

In this video, Nancy S. Reau, MD, FAASLD, AGAF, discusses long-term data from the ELATIVE open-label extension trial of Iqirvo in patients with primary biliary cholangitis.Results presented at The ...
Yahoo Finance

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

FOSTER CITY, Calif., October 23, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with ...
Seeking Alpha

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

New data from the ELATIVE ® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks ...
Business Wire

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) have entered ...
Business Wire

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% ...
Morningstar

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Three late-breaking presentations will share new data on Livdelzi® (seladelpar) in people living with primary biliary cholangitis (PBC), including real-world treatment experience following the ...